Advertisement

Protocatechuic acid attenuate depressive-like behavior in olfactory bulbectomized rat model: behavioral and neurobiochemical investigations

  • Vishnu N. Thakare
  • Rajesh R. Patil
  • Anupama A. Suralkar
  • Valmik D. Dhakane
  • Bhoomika M. PatelEmail author
Original Article
  • 27 Downloads

Abstract

The main objective of the present study is to investigate potential effects of PCA in OBX induced depressive-like behavior in rat model. PCA was administered at a dose of 100 mg/kg and 200 mg/kg, by per oral in OBX and sham operated rats. Behavioral (ambulatory and rearing activity and immobility time), neurochemical [serotonin (5-HT), dopamine (DA), norepinephrine (NE) and brain derived neurotrophic factor (BDNF) expression], biochemical (MDA formation, IL-6, TNF-α and antioxidants) changes in hippocampus and cerebral cortex along with serum corticosterone were investigated. Experimental findings reveals that OBX subjected rats showed alteration in behaviors like, increase in immobility time, ambulatory and rearing behaviors significantly, reduced BDNF level, 5-HT, DA,NE and antioxidant parameters along with increased serum corticosterone, MDA formation, IL-6, and TNF-α in hippocampus and cerebral cortex compared to sham operated rats. Administration of PCA significantly attenuated behavioral and neurobiochemical alterations, thus, its antidepressant-like activity is largely mediated through modulation of neurotransmitter, endocrine and immunologic systems, mainly by improvements of BDNF, 5-HT, DA, NE, reduced MDA, IL-6, and TNF-α in hippocampus and cerebral cortex.

Keywords

PCA Olfactory bulbectomy Neurobiochemical alterations Oxidative stress 

Notes

Acknowledgements

Authors are grateful to Prof. M. N. Navale, Founder President, STES, Pune, and Dr. R.N. Kane, Principal, Sinhgad Institute of Pharmaceutical Sciences, Lonavala for providing necessary infrastructural facility, and support in the completion of present research work.

Compliance with ethical standards

Conflict of interests

The authors declare that there are no conflicts of interest.

References

  1. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126CrossRefGoogle Scholar
  2. Antunes MS, Jesse CR, Ruff JR, de Oliveira Espinosa D, Gomes NS, Altvater EET, Donato F, Giacomeli R, Boeira SP (2016) Hesperidin reverses cognitive and depressive disturbances induced by olfactory bulbectomy in mice by modulating hippocampal neurotrophins and cytokine levels and acetylcholinesterase activity. Eur J Pharmacol 789:411–420CrossRefGoogle Scholar
  3. Cairncross KD, Wren A, Cox B, Schnieden H (1977) Effects of olfactory bulbectomy and domicile on stress-induced corticosterone release in the rat. Physiol Behav 19:485–487CrossRefGoogle Scholar
  4. Duman RS (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. NeuroMolecular Med 5:11–25CrossRefGoogle Scholar
  5. Elhwuegi AS (2004) Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28:435–451CrossRefGoogle Scholar
  6. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–72CrossRefGoogle Scholar
  7. Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G et al (2011) Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 45:995–1004CrossRefGoogle Scholar
  8. Fuchs E, Czéh B, Kole MH et al (2004) Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol 14:S481–S490CrossRefGoogle Scholar
  9. Jindal A, Mahesh R, Bhatt S (2015a) Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: involvement of hypothalamic–pituitary–adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacol Biochem Behav 132:20–32CrossRefGoogle Scholar
  10. Jindal A, Mahesh R, Bhatt S (2015b) Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy. Psychopharmacology (Berlin) 232:623–637CrossRefGoogle Scholar
  11. Kaster MP, Gadotti VM, Calixto JB (2012) Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacol 62:419–426CrossRefGoogle Scholar
  12. Kim JH, Kim GH, Hwang KH (2012) Monoamine oxidase and dopamine b-hydroxylase inhibitors from the fruits of Gardenia jasminoides. BiomolTher 20:214–219Google Scholar
  13. Kim YS, Seo HW, Lee MH, Kim DK, Jeon H, Cha DS (2014) Protocatechuic acid extends lifespan and increases stress resistance in Caenorhabditis elegans. Archives of Pharmacal Research 37(2):245–252Google Scholar
  14. Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51(6):1562–1566Google Scholar
  15. Manji HK, Duman RS (2001) Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull l35:5–49Google Scholar
  16. Mao Q, Xian YF, Ip SP et al (2010) Long-term treatment with peony glycosides reverses chronic unpredictable mild stress-induced depressive-like behavior via increasing expression of neurotrophins in rat brain. Behav Brain Res 210:171–177CrossRefGoogle Scholar
  17. Mao QQ, Xian YF, Ip SP, Che CT (2011) Involvement of serotonergic system in the antidepressant-like effect of piperine. Prog Neuropsychopharmacol Biol Psychiatry 35:1144–1147CrossRefGoogle Scholar
  18. Mao QQ, Huang Z, Zhong X et al (2014) Brain-derived neurotrophic factor signalling mediates the antidepressant-like effect of piperine in chronically stressed mice. Behav Brain Res 26:140–145CrossRefGoogle Scholar
  19. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC (2009) Changes in BDNF serum levels in patients with major depression disorder MDD after 6months treatment with sertraline escitalopram or venlafaxine. J Psychiatr Res 43:247–254CrossRefGoogle Scholar
  20. Muley MM, Thakare VN, Patil RR, Kshirsagar AD, Naik SR (2012) Silymarin improves the behavioural, biochemical and histoarchitecture alterations in focal ischemic rats: comparative evaluation with piracetam and protocatachuic acid. Pharmacol Biochem Behav 102:286–293CrossRefGoogle Scholar
  21. Muley MM, Thakare VN, Patil RR, Bafna PA, Naik SR (2013) Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. Life Sci 93:51–57CrossRefGoogle Scholar
  22. Numakawa T, Matsumoto T, Numakawa Y, Richards M, Yamawaki S, Kunugi H (2011) Protective Action of Neurotrophic Factors and Estrogen against Oxidative Stress-Mediated Neurodegeneration. Journal of Toxicology 2011:1–12Google Scholar
  23. Nutt DJ (2008) Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69:4–7CrossRefGoogle Scholar
  24. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefGoogle Scholar
  25. Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464–468CrossRefGoogle Scholar
  26. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327–336Google Scholar
  27. Rang HP, Dale MM, Ritter JM, Flower RJ (2007) Selective serotonin reuptake inhibitors. Pharmacology, pp 566. Churchill Livingstone, Elsevier PublicationGoogle Scholar
  28. Rinwa P, Kumar A (2014) Panax quinquefolium involves nitric oxide pathway in olfactory bulbectomy rat model. Physiol Behav 129:142–151CrossRefGoogle Scholar
  29. Rodrigues ALS, Rocha JBT, Mello CF, Souza DO (1996) Effect of perinatal Lead exposure on rat behaviour in open-field and two-Wky avoidance tasks. Basic Clin Pharmacol Toxicol 79:150–156CrossRefGoogle Scholar
  30. Rosa JM, Dafre AL, Rodrigues AL (2013) Antidepressant-like responses in the forced swimming test elicited by glutathione and redox modulation. Behavioural Brain Research 253:165–172Google Scholar
  31. Schiepers OJ, Wichers MC, Maes M (2005) Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29:201–217CrossRefGoogle Scholar
  32. Shellenberger MK, Gordon JH (1971) A rapid, simplified procedure for simultaneous assay of norepinephrine, dopamine, and 5-hydroxytryptamine from discrete brain areas. Anal Biochem 39:356–372CrossRefGoogle Scholar
  33. Shen J, Ma LG, Hu CY, Pei YY, Jin SL, Fang XY, Li YC (2016) Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice. Neurosci Lett 614:77–82CrossRefGoogle Scholar
  34. Shi GF, An LJ, Jiang B, Guan SI, Bao YM (2006) Alpinia protocatechuic acid protects against oxidative damage in vitro and reduces oxidative stress in vivo. Neurosci Lett 403:206–210CrossRefGoogle Scholar
  35. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada SI, Iyo M (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54:70–75CrossRefGoogle Scholar
  36. Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627–647CrossRefGoogle Scholar
  37. Tang MM, Lin WJ, Pan YQ, Guan XT, Li YC (2016) Hippocampal neurogenesis dysfunction linked to depressive-like behaviors in a neuroinflammation induced model of depression. Physiol Behav 161:166–173CrossRefGoogle Scholar
  38. Thakare VN, Patel BM (2015) Potential targets for the development of novel antidepressants: future perspectives. CNS Neurol Disord Drug Targets 14:270–281CrossRefGoogle Scholar
  39. Thakare VN, Dhakane VD, Patel BM (2016) Potential antidepressant-like activity of silymarin in the acute restraint stress in mice: modulation of corticosterone and oxidative stress response in cerebral cortex and hippocampus. Pharmacol Rep 68:1020–1027CrossRefGoogle Scholar
  40. Thakare VN, Dhakane VD, Patel BM (2017a) Attenuation of acute restraint stress-induced depressive like behavior and hippocampal alterations with protocatechuic acid treatment in mice. Metab Brain Dis 32:401–413CrossRefGoogle Scholar
  41. Thakare VN, Aswar MK, Kulkarni YP, Patil RR, Patel BM (2017b) Silymarin ameliorates experimentally induced depressive like behavior in rats: involvement of hippocampal BDNF signaling, inflammatory cytokines and oxidative stress response. Physiol Behav 179:401–410CrossRefGoogle Scholar
  42. Van Reizen H, Leonard BE (1990) Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomised rats. Pharmacol Ther 47:21–34CrossRefGoogle Scholar
  43. Youdim MB, Weinstock M (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25:243–250CrossRefGoogle Scholar
  44. Zhang H, Li G, Szeto S, Chong C, Quan Q et al (2015) Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson's disease. Free Radic Biol Med 84:331–333CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacologySinhgad Institute of Pharmaceutical SciencesLonavalaIndia
  2. 2.Department of Pharmacology, Institute of PharmacyNirma UniversityAhmedabadIndia
  3. 3.Department of PharmacologySmt. Kashibai Navale College of PharmacyPuneIndia
  4. 4.Research and DevelopmentAstec Life SciencesMumbaiIndia

Personalised recommendations